Bone Density Among Long-term Users Of Medroxyprogesterone Acetate As A Contraceptive.

dc.creatorPaiva, L C
dc.creatorPinto-Neto, A M
dc.creatorFaundes, A
dc.date1998-Dec
dc.date2015-11-27T12:19:29Z
dc.date2015-11-27T12:19:29Z
dc.date.accessioned2018-03-29T00:53:17Z
dc.date.available2018-03-29T00:53:17Z
dc.identifierContraception. v. 58, n. 6, p. 351-5, 1998-Dec.
dc.identifier0010-7824
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/10095971
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/194304
dc.identifier10095971
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1294537
dc.descriptionThe bone density (BD) of 72 women using depot-medroxyprogesterone acetate (DMPA) for at least 1 year was compared with that of 64 women who were not users of hormonal contraceptives. The BD of lumbar spine, femoral neck, Ward's triangle, and trochanter was measured by dual energy X-ray absorptiometry (DEXA-LUNAR DPX). Estradiol (E2) concentrations were measured by radioimmunoassay (RIA). The mean age of DMPA users and nonusers was 31.8 and 31.1 years, respectively. Mean E, was 55.7 pg/mL for users and 149.9 pg/mL for controls (p < 0.001). The BD was significantly lower for DMPA users than for controls in all sites (p < 0.01). In addition, young adult T-scores in the lumbar spine were significantly lower among DMPA users than in controls (p < 0.01). Differences were maintained in a subsample of 47 women per group paired by age and body mass index (BMI). Multiple regression analysis showed that older age, lower BMI, and longer amenorrhea were associated with lower BD in the femoral neck, whereas lower BMI and use of DMPA were associated with lower BD in the lumbar spine.
dc.description58
dc.description351-5
dc.languageeng
dc.relationContraception
dc.relationContraception
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAbsorptiometry, Photon
dc.subjectAdult
dc.subjectBone Density
dc.subjectContraceptive Agents, Female
dc.subjectCross-sectional Studies
dc.subjectEstradiol
dc.subjectFemale
dc.subjectHumans
dc.subjectMedroxyprogesterone Acetate
dc.subjectProgesterone Congeners
dc.subjectRadioimmunoassay
dc.subjectRegression Analysis
dc.subjectTime Factors
dc.subjectAmericas
dc.subjectBiology
dc.subjectBrazil
dc.subjectComparative Studies
dc.subjectContraception
dc.subjectContraceptive Agents, Female--pharmacodynamics
dc.subjectContraceptive Agents, Progestin--pharmacodynamics
dc.subjectContraceptive Agents--pharmacodynamics
dc.subjectContraceptive Methods--side Effects
dc.subjectDemographic Factors
dc.subjectDepo-provera--pharmacodynamics
dc.subjectDeveloping Countries
dc.subjectFamily Planning
dc.subjectInjectables--side Effects
dc.subjectLatin America
dc.subjectLongterm Effects--women
dc.subjectMedroxyprogesterone Acetate--pharmacodynamics
dc.subjectPhysiology
dc.subjectPopulation
dc.subjectPopulation Dynamics
dc.subjectResearch Methodology
dc.subjectResearch Report
dc.subjectRisk Factors--women
dc.subjectSkeletal Effects--women
dc.subjectSouth America
dc.subjectStudies
dc.subjectTime Factors
dc.subjectWomen
dc.titleBone Density Among Long-term Users Of Medroxyprogesterone Acetate As A Contraceptive.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución